无症状颈动脉狭窄的综合评估与管理策略:批判性综述与网状Meta分析
结果显示BMT的30天卒中风险低于CEA,而CEA在非围手术期长期卒中方面优于BMT;CAS早期神经事件点估计值较高但精度有限,长期结局与CEA大致相当。
要点
- BMT的30天卒中及卒中/死亡风险低于CEA,围手术期安全性更优。
- CEA较BMT降低非围手术期长期卒中风险,长期获益明确。
- CAS早期神经事件风险可能较高,长期结局与CEA大致相当但证据不精确。
核心结论
- 在无症状颈动脉狭窄的RCT证据中,BMT的30天安全性最佳,CEA较BMT降低非围手术期长期卒中风险。
- CAS可能早期神经风险更高,长期结局与CEA大致可比,现代队列同侧卒中优势仅为假设生成。
研究设计与样本
- 纳入标准为≥50%无症状颈动脉狭窄患者,比较CEA、CAS与BMT,并区分2000年前传统BMT与2000年后现代BMT。
主要发现
- 与CEA相比,BMT的30天卒中OR为0.29(95%CI 0.16-0.55),30天卒中/死亡OR为0.26(95%CI 0.15-0.44)。
- CAS对比CEA的30天卒中/死亡OR为1.71(95%CI 0.97-2.99),精度有限。
- 非围手术期长期卒中方面BMT对比CEA的OR为2.22(95%CI 1.70-2.90),CAS对比CEA的OR为1.09(95%CI 0.85-1.41)。
- 2000年后亚组中,30天后同侧卒中CAS对比CEA的OR为0.84(95%CI 0.32-2.19),结果不精确。
关键数值与推荐
- 纳入RCT中无症状颈动脉狭窄定义为≥50%狭窄。
- 结局指标包括30天卒中与死亡、长期卒中(30天至10年)及卒中亚型(主要、次要、同侧、对侧)。
- 采用累积排序曲线下面积(SUCRA)作为支持性总结,并结合效应量与不确定性解读。
临床怎么用
- 临床决策应优先评估绝对风险、患者个体化手术风险及对强化药物治疗的持续依从性。
- BMT应作为围手术期安全性优先的基线策略,CEA用于长期卒中风险获益人群,CAS需权衡早期神经事件风险。
局限性
- 2000年切点对「现代」治疗的划分可能存在错分,现代队列同侧卒中优势的置信区间较宽。
- CAS相关复合终点的精度有限,部分结局的可提取数据受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Management of asymptomatic carotid artery stenosis (ACAS) is variable, including carotid endarterectomy (CEA), carotid artery stenting (CAS), and best medical treatment (BMT). The contemporary risk-benefit profiles of invasive versus medical therapies remain unclear. METHODS: A systematic review and network meta-analyses were conducted using data from randomized controlled trials (RCTs) including patients with ≥50% ACAS. Outcomes assessed were 30-day stroke and mortality, long-term stroke (30 days-10 years), and stroke subtypes (major, minor, ipsilateral, contralateral). Traditional (pre-2000) and modern (post-2000) BMT were compared to assess temporal improvements in medical therapy. RESULTS: Eleven RCTs (14,295 randomized participants) were identified; 9 trials contributed extractable asymptomatic data (12,320 participants) to at least one endpoint-specific network meta-analysis. Compared with CEA, BMT was associated with lower odds of 30-day stroke (odds ratio [OR]: 0.29, 95% confidence interval [CI]: 0.16-0.55) and 30-day stroke/death (OR: 0.26, 95% CI: 0.15-0.44). CAS showed higher point estimates for early neurologic events versus CEA, but precision was limited for composites (e.g., 30-day stroke/death OR: 1.71, 95% CI: 0.97-2.99). For nonprocedural long-term stroke, CEA was associated with lower odds than BMT (BMT versus CEA OR: 2.22, 95% CI: 1.70-2.90), whereas CAS and CEA were similar (CAS versus CEA OR: 1.09, 95% CI: 0.85-1.41). In the post-2000 subset, ipsilateral stroke after 30 days numerically favored CAS versus CEA (OR: 0.84, 95% CI: 0.32-2.19) but remained imprecise. Surface Under the Cumulative Ranking were used as supportive summaries and interpreted in the context of effect sizes and uncertainty. CONCLUSION: In RCT evidence for ACAS, BMT was associated with the most favorable 30-day profile, while CEA reduced nonprocedural long-term stroke versus BMT. CAS may carry higher early neurologic risk, with long-term outcomes largely comparable to CEA; a possible modern-era advantage for ipsilateral stroke is hypothesis-generating given wide CIs and potential misclassification of "modern" therapy around the year-2000 cut point. Contemporary decision-making should prioritize absolute risks, patient-specific procedural risk, and sustained adherence to intensive medical therapy.
引用
- Lübke T, Lisii C, Heckenkamp J, et al. Comprehensive Evaluation and Management Strategies for Asymptomatic Carotid Artery Stenosis: A Critical Review and Network Meta-Analysis. Ann Vasc Surg. 2026. PMID: 41967668. doi:10.1016/j.avsg.2026.03.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。